Open Orphan PLC - pharmaceutical services company - Wins a new contract with Codagenix Inc to conduct a first in human phase 1 trial of a Covid-19 vaccine candidate, CodaVax-COVID. The trial will evaluate the safety of a single dose of the SARS-CoV-2 intranasal vaccine as well as its ability to generate an immune response. The vaccine study will involve 48 healthy volunteers and will begin in early autumn, with initial data due by the end of 2020. The study will also include a second dose as a surrogate viral challenge on day 28.
Current stock price: 13.00 pence
Year-to-date change: up more than 100%
By Anna Farley; email@example.com
Copyright 2020 Alliance News Limited. All Rights Reserved.